Brown Medical School

HEPPigram: Management of the Abacavir Hypersensitivity Syndrome (AHS)

January 2002

This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Approximately 3%-5% of patients who are on Abacavir (ABC) antiretroviral therapy experience what is known as the Abacavir Hypersensitivity Syndrome (AHS) within the first six weeks of therapy. It is important to counsel patients about AHS before they begin treatment and to contact medical staff immediately if symptoms should occur within the first six weeks of treatment. Additionally, they should be counseled NOT to discontinue the medication on their own, as it would confuse later decision making. This algorithm describes the management of AHS.

Management of the Abacavir Hypersensitivity Syndrome (AHS)

It is important NOT to stop the ABC when symptoms first appear, without further investigation as described above, as they are indistinguishable from a viral syndrome. Because AHS is not dangerous if detected early, clinicians can have the opportunity to follow the patient and determine if the patient's symptoms disappear. If, on the other hand, the ABC is stopped before confirmation of AHS, it could preclude the use of a truly potent antiretroviral that the patient might need in the future. Unfortunately, once stopped in the event of symptoms, ABC can never be used again.

Back to the HEPP News January 2002 contents page.

This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

This article was provided by Brown Medical School. It is a part of the publication HEPP News.

More on HIV Medications

My Health Tracker

Widgets and RSS Feeds

U.S. ASO Finder

The First Man to Be Cured of AIDS: An Update on the Amazing Story -- This Month in HIV

OIs and Co-Infections and STIs -- Oh, My!

World AIDS Day 2009: Home

HIV Antiretrovirals in Development: An Update From ICAAC 2009

Back From the Brink: A Blog Entry by Thomas DeLorenzo

More >>

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.